ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "psoriasis and psoriatic arthritis"

  • Abstract Number: 2075 • 2018 ACR/ARHP Annual Meeting

    Vascular Endothelial and Inflammatory Differences in Psoriasis and Psoriatic Arthritis Patients

    Michael Gashick1, Todd Wechter2, Tessa Barrett1, Sarah Azarchi2, Stuart Katz3, Andrea L. Neimann4, James Krueger5, Sanja Jelic6, Edward Fisher1, Jose U. Scher7 and Jeffrey S. Berger8, 1Medicine/Cardiology, New York University School of Medicine, New York City, NY, 2Dermatology, New York University School of Medicine, New York City, NY, 3Medicine/Cardiology, New York University School of Medicine, New York, NY, 4Department of Dermatology, New York University School of Medicine, New York, NY, 5The Rockefeller University, New York, NY, 6Medicine/Pulmonary, Columbia University Medical Center, New York City, NY, 7New York University School of Medicine, New York, NY, 8Medicine, Division of Cardiology, New York University School of Medicine, New York, NY

    Background/Purpose: Psoriatic arthritis (PsA) and Psoriasis (PsO) are chronic inflammatory diseases associated with vascular inflammation and increased CVD risk. Few studies have examined vascular inflammatory…
  • Abstract Number: 2134 • 2018 ACR/ARHP Annual Meeting

    Modifiable Risk Factors and the Development of Psoriatic Arthritis in People with Psoriasis

    Amelia Green1,2, Gavin Shaddick3, Rachel Charlton1, Julia Snowball1, Alison L Nightingale1, Catherine Smith4, William Tillet1,5 and Neil McHugh1,5, 1Department of Pharmacy and Pharmacology, The University of Bath, Bath, United Kingdom, 2Department of Mathematical Sciences, The University of Bath, Bath, United Kingdom, 3Centre for Data Science and Statistics, The University of Exeter, Bath, United Kingdom, 4Guy’s and St Thomas’ NHS Foundation Trust, St John’s Institute of Dermatology, London, United Kingdom, 5Royal National Hospital for Rheumatic Diseases, Bath, UK, Bath, United Kingdom

    Background/Purpose: Psoriatic Arthritis (PsA) is a progressive and often destructive joint disease that causes pain, swelling and joint stiffness, and can lead to an impaired…
  • Abstract Number: 2879 • 2017 ACR/ARHP Annual Meeting

    Switching from Adalimumab to Chs-1420: A Randomized, Double-Blind Global Clinical Trial in Patients with Psoriasis and Psoriatic Arthritis

    Jennifer Hodge, Hong Tang, Paula O'Connor and Barbara Finck, Coherus BioSciences, Inc., Redwood City, CA

    Background/Purpose: CHS-1420 is a proposed biosimilar to adalimumab. A phase 3, randomized, double-blind, multicenter study evaluated the equivalence of CHS-1420 to adalimumab in patients with…
  • Abstract Number: 2973 • 2017 ACR/ARHP Annual Meeting

    Detection of Clinical Signs of Arthritis and Subclinical Evidence of Inflammation in Psoriasis Patients with Risk for Arthritis: Value of Clinical Examination, Ultrasound and Fluorescence-Optical Imaging – Results from the Prospective Multicentre Xciting Study

    Michaela Koehm1, Tanja Rossmanith2, Hans-Eckhard Langer3, Marina Backhaus4, Gerd R. Burmester5, Siegfried Wassenberg6, Benjamin Köhler6, Harald Burkhardt7 and Frank Behrens8, 1Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt/Main, Germany, 2Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt, Germany, 3RHIO (Rheumatology, Immunology, Osteology) Duesseldorf, Duesseldorf, Germany, 4Rheumatology, Park-Klinik Weissensee, Berlin, Germany, 5Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, 6Rheumazentrum Ratingen, Ratingen, Germany, 7Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany, 8Clinical Research Rheumatology and Fraunhofer Institute IMETranslation, Goethe University, Frankfurt, Germany

    Background/Purpose: Psoriasis (Pso) is one of the most common chronic inflammatory skin diseases in Europe. Psoriatic arthritis (PsA) is closely associated to Pso whereas the…
  • Abstract Number: 597 • 2017 ACR/ARHP Annual Meeting

    Ixekizumab Improves Patient-Reported Outcomes through 52 Weeks in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to Tumor Necrosis Factor-Inhibitors

    Arthur Kavanaugh1, Helena Marzo-Ortega2, Ronald Vender3, Julie Birt4, David Adams4, Olivier Benichou4, Chen-Yen Lin4 and Peter Nash5, 1Medicine, University of California, San Diego, La Jolla, CA, 2Department of Rheumatology, Chapel Allerton Hospital, Leeds, United Kingdom, 3Dermatrials Research, Inc., Hamilton, ON, Canada, 4Eli Lilly and Company, Indianapolis, IN, 5University of Queensland, Brisbane, Australia

    Background/Purpose: Ixekizumab (IXE) is a high affinity monoclonal antibody that selectively targets interleukin-17A. Up to 24 weeks, IXE was superior to placebo (PBO) in improving…
  • Abstract Number: 607 • 2017 ACR/ARHP Annual Meeting

    Secukinumab Treatment of Psoriatic Arthritis and Moderate to Severe Psoriasis Relieves Anxiety/Depression up to 52 Weeks: An Overview from Secukinumab Phase 3 Clinical Trials

    Philip J Mease1, Mark Lebwohl2, Isabelle Gilloteau3, Todd Fox3, Jaime Oliver3, Steffen Jugl3 and Alice B Gottlieb4, 1University of Washington School of Medicine and Swedish Medical Center, Seattle, WA, 2Icahn School of Medicine at Mount Sinai, New York, NY, 3Novartis Pharma AG, Basel, Switzerland, 4Department of Dermatology, New York Medical College, Vallhalla, NY

    Background/Purpose: Secukinumab (SEC), a fully human monoclonal antibody selectively neutralizing interleukin-17A, exhibits significant efficacy, with a favorable safety profile, in the treatment of psoriatic arthritis…
  • Abstract Number: 628 • 2017 ACR/ARHP Annual Meeting

    Integrated Efficacy Results from Two Phase 3 Trials of Ixekizumab for the Treatment of Psoriatic Arthritis

    Bernard Combe1, Peter Nash2, David Adams3, Lisa Kerr3 and Olivier Benichou3, 1Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France, 2University of Queensland, Brisbane, Australia, 3Eli Lilly and Company, Indianapolis, IN

    Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that selectively targets interleukin-17A. Here, we present integrated efficacy data at Week 24 from two phase 3…
  • Abstract Number: 647 • 2017 ACR/ARHP Annual Meeting

    Gene Expression in Cellular Subsets in Psoriatic Disease

    Anastasiya Muntyanu1, Fatima Abji2, Remy Pollock1, Vinod Chandran2 and Dafna D Gladman2, 1University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Psoriatic arthritis is an inflammatory musculoskeletal disease which develops in 30% of patients with psoriasis. Our previous peripheral blood microarray study identified CXCL10, NOTCH2NL,…
  • Abstract Number: 994 • 2017 ACR/ARHP Annual Meeting

    Increasing Population Burden of Psoriatic Disease in Ontario, Canada – a Longitudinal Cohort Study

    Lihi Eder1,2, Jessica Widdifield3, Cheryl F. Rosen4, Dafna D Gladman2,5, Raed Alhusayen6, Michael Paterson7, Stephanie Cheng7, Shirin Jabbari7, Willemina Campbell8, Sasha Bernatsky9 and Karen Tu7, 1Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada, 2Medicine, University of Toronto, Toronto, ON, Canada, 3University Health Network, Toronto, ON, Canada, 4Dermatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, 5Rheumatology, University Health Network, Toronto, ON, Canada, 6Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 7Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, 8Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, 9Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada

    Background/Purpose: There is limited information on the epidemiology of psoriasis and psoriatic arthritis (PsA) in North America. The aims of this study were to estimate…
  • Abstract Number: 995 • 2017 ACR/ARHP Annual Meeting

    The Epidemiology of Psoriatic Arthritis in Israel – a Population-Based Study

    Lihi Eder1,2, Arnon Dov Cohen3, Ilan Feldhamer4, Sari Greenberg-Dotan4, Eraz Batat4 and Devy Zisman5, 1Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada, 2Medicine, University of Toronto, Toronto, ON, Canada, 33Chief Physician’s Office, Central Headquarters, Clalit Health Services, Tel Aviv, Israel, 4Chief Physician’s Office, Central Headquarters, Clalit Health Services, Tel Aviv, Israel, 5The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel

    Background/Purpose: There is limited information on the epidemiology of Psoriatic Arthritis (PsA) in general and in Middle Eastern populations in particular. The aims of this…
  • Abstract Number: 996 • 2017 ACR/ARHP Annual Meeting

    Accuracy of Canadian Administrative Health Data in Identifying Patients with Psoriasis and Psoriatic Arthritis Using Primary Care Medical Records As the Reference Standard

    Lihi Eder1,2, Jessica Widdifield3, Cheryl F. Rosen4, Dafna D Gladman2, Raed Alhusayen5, Michael Paterson6, Stephanie Cheng6, Shirin Jabbari6, Willemina Campbell7, Sasha Bernatsky8 and Karen Tu6, 1Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada, 2Medicine, University of Toronto, Toronto, ON, Canada, 3University Health Network, Toronto, ON, Canada, 4Dermatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, 5Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 6Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, 7Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, 8Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada

    Background/Purpose: We assessed the accuracy of algorithms to identify patients with psoriasis and psoriatic arthritis (PsA) in administrative health data in a validation set derived…
  • Abstract Number: 1558 • 2017 ACR/ARHP Annual Meeting

    Changes in Blood Pressure with TNF Inhibitors for Psoriatic Arthritis

    Birju D. Bhatt1, J. Lynn Palmer2, Jeffrey R. Curtis3, Sathya Velkuru4 and Joel Kremer5, 1Medicine, div-of Rheumatology, Albany Medical College, Albany, NY, 2Corrona Research Foundation, Albany, NY, 3Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, 4Medicine, Albany Medical College, Albany, NY, 5Albany Medical College and the Center for Rheumatology, Albany, NY

    Background/Purpose:  Psoriasis is a complex disorder with cutaneous and rheumatological manifestations affecting 2-3% of the population of the Western world. The prevalence of hypertension (HTN)…
  • Abstract Number: 1571 • 2017 ACR/ARHP Annual Meeting

    Bimekizumab Dual Inhibition of IL-17A and IL-17F Provides Evidence of IL-17F Contribution to Chronic Inflammation in Disease-Relevant Cells

    Ash Maroof1, Remi Okoye1, Tim Smallie1, Dominique Baeten2,3, Sophie Archer1, Catherine Simpson1, Meryn Griffiths1 and Stevan Shaw1, 1UCB Pharma, Slough, United Kingdom, 2UCB Pharma, Brussels, Belgium, 3University of Amsterdam, Amsterdam, Netherlands

    Background/Purpose: IL-17A and IL-17F share structural homology and have similar biologic function.1 Although the contribution of IL-17A to immune-mediated inflammatory diseases has been widely reported,1,2…
  • Abstract Number: 1577 • 2017 ACR/ARHP Annual Meeting

    Deciphering the Role of the Tissue Microenvironment in Shaping the Immune Landscape in Psoriatic Arthritis

    Jin Hui Sherlynn Chan1, Ying Ying Leung2, Warren Fong2, Yi Wei Yeo2, Bhairav Paleja1, Liyun Lai1, Suzan Saidin1, Camillus Chua1, Sharifah Nur Hazirah1, Su Li Poh1, Andrea Hsiu Ling Low2 and Salvatore Albani1,3, 1SingHealth Translational Immunology and Inflammation Centre (STIIC), Duke-NUS Medical School, Singapore, Singapore, 2Singapore General Hospital, Singapore, Singapore, 3KK Women's and Children's Hospital, Singapore, Singapore

    Background/Purpose: Psoriatic arthritis (PsA) occurs in a third of patients with psoriasis (Ps) and up to 30% of patients with PsA do not have an…
  • Abstract Number: 1912 • 2017 ACR/ARHP Annual Meeting

    Broad Immunophenotyping Results: CCR10 Expressing CD8 T Cells Distinguish Psoriatic Arthritis from Psoriasis Limited to Skin Involvement

    Emmerik F.A. Leijten1,2, Tessa S. van Kempen1,2, Michel A.M. Olde Nordkamp1,2, Fleurieke H. Verhagen2,3, Sanne Hiddingh2,3, Jonas J.W. Kuiper2,3, Marianne L. Boes2,4 and Timothy R.D.J. Radstake1,2, 1Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 2Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 3Ophthalmology, University Medical Center Utrecht, Utrecht, Netherlands, 4Department of Pediatrics, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose: Studies that compare the immune cell phenotype or function from patients with psoriatic arthritis (PsA) to patients with psoriasis limited to cutaneous involvement (Pso)…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology